OncoMatch/Clinical Trials/NCT06397222
Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
Is NCT06397222 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Sin-Bev-SIRT for hepatocellular carcinoma non-resectable.
Treatment: Sin-Bev-SIRT — This study is conducted to evaluate the efficacy and safety of sintilimab, bevacizumab plus Y-90 selective internal radiation therapy (SIRT) for patients with unresectable intermediate-advanced hepatocellular carcinoma (HCC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage BCLC STAGE B, BCLC STAGE C, CNLC II, CNLC III
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: hepatic arterial infusion chemotherapy
Patients who previously received hepatic arterial infusion chemotherapy (HAIC)
Cannot have received: transarterial chemoembolization
transarterial chemoembolization (TACE)
Cannot have received: transarterial embolization
transarterial embolization (TAE)
Cannot have received: radiation therapy
radiotherapy
Cannot have received: systemic therapy
systemic therapy for HCC
Lab requirements
Blood counts
Peripheral blood white blood cell count ≥3×10^9/L and platelet count ≥50×10^9/L
Liver function
Child-Pugh score 5-7; no hepatic dysfunction such as ascites, esophagogastric varices, hepatic encephalopathy; no evidence of portal hypertension with high risk of bleeding; prolonged prothrombin time >4 seconds excluded
Child-Pugh score 5-7. Hepatic dysfunction, such as ascites, esophagogastric varices, hepatic encephalopathy [excluded]. Evidence of portal hypertension with high risk of bleeding [excluded]. Peripheral blood white blood cell count <3×10^9/L and platelet count <50×10^9/L [excluded]. Prolonged prothrombin time >4 seconds [excluded]. Severe organ (heart, lung, kidney) dysfunction [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06397222 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage BCLC STAGE B or BCLC STAGE C or CNLC II or CNLC III is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages